Cargando…

Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and he...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Youhua, Xu, Junhong, Ma, Bing, Chen, Guohua, Wang, Zhibin, Wang, Shanmei, Jing, Nan, Zhang, Jiangfeng, Wang, Baoya, Yan, Wenjuan, Zhang, Qi, Zhao, Qiongrui, Li, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020218/
https://www.ncbi.nlm.nih.gov/pubmed/36936962
http://dx.doi.org/10.3389/fimmu.2023.1107866
_version_ 1784908205326860288
author Yuan, Youhua
Xu, Junhong
Ma, Bing
Chen, Guohua
Wang, Zhibin
Wang, Shanmei
Jing, Nan
Zhang, Jiangfeng
Wang, Baoya
Yan, Wenjuan
Zhang, Qi
Zhao, Qiongrui
Li, Yi
author_facet Yuan, Youhua
Xu, Junhong
Ma, Bing
Chen, Guohua
Wang, Zhibin
Wang, Shanmei
Jing, Nan
Zhang, Jiangfeng
Wang, Baoya
Yan, Wenjuan
Zhang, Qi
Zhao, Qiongrui
Li, Yi
author_sort Yuan, Youhua
collection PubMed
description INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination. METHODS: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months. RESULTS: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported. DISCUSSION: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.
format Online
Article
Text
id pubmed-10020218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100202182023-03-18 Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study Yuan, Youhua Xu, Junhong Ma, Bing Chen, Guohua Wang, Zhibin Wang, Shanmei Jing, Nan Zhang, Jiangfeng Wang, Baoya Yan, Wenjuan Zhang, Qi Zhao, Qiongrui Li, Yi Front Immunol Immunology INTRODUCTION: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination. METHODS: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months. RESULTS: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26–50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60–90 days, decreased, and stabilized at 82.9% at 181–240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported. DISCUSSION: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations. Frontiers Media S.A. 2023-03-03 /pmc/articles/PMC10020218/ /pubmed/36936962 http://dx.doi.org/10.3389/fimmu.2023.1107866 Text en Copyright © 2023 Yuan, Xu, Ma, Chen, Wang, Wang, Jing, Zhang, Wang, Yan, Zhang, Zhao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yuan, Youhua
Xu, Junhong
Ma, Bing
Chen, Guohua
Wang, Zhibin
Wang, Shanmei
Jing, Nan
Zhang, Jiangfeng
Wang, Baoya
Yan, Wenjuan
Zhang, Qi
Zhao, Qiongrui
Li, Yi
Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title_full Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title_fullStr Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title_full_unstemmed Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title_short Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
title_sort characteristics of humoral and cellular responses to coronavirus disease 2019 (covid-19) inactivated vaccine in central china: a prospective, multicenter, longitudinal study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020218/
https://www.ncbi.nlm.nih.gov/pubmed/36936962
http://dx.doi.org/10.3389/fimmu.2023.1107866
work_keys_str_mv AT yuanyouhua characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT xujunhong characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT mabing characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT chenguohua characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT wangzhibin characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT wangshanmei characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT jingnan characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT zhangjiangfeng characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT wangbaoya characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT yanwenjuan characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT zhangqi characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT zhaoqiongrui characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy
AT liyi characteristicsofhumoralandcellularresponsestocoronavirusdisease2019covid19inactivatedvaccineincentralchinaaprospectivemulticenterlongitudinalstudy